Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study
Journal of the European Academy of Dermatology and Venereology · 2026-09 · 40 (9) · 1481-1489
DOI: 10.1111/jdv.70291 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 23.01.2026. Verfasst von Victoria P Werth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Biogen.
Abstract (Originalsprache)
Background
Cutaneous lupus erythematosus (CLE) has no approved targeted therapies. In Part B of the randomized, double‐blind, placebo‐controlled, Phase 2 LILAC study, litifilimab demonstrated a dose–response relationship for percentage change in Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI‐A) score from baseline to Week 16.
Objectives
These post hoc analyses of Part B of the LILAC study aimed to assess the efficacy of litifilimab on additional skin‐specific outcomes.
Methods
Adult participants with baseline CLASI‐A score ≥8 and histologically confirmed CLE, with/without systemic manifestations, received litifilimab 50 mg, 150 mg or 450 mg, or placebo subcutaneously every 4 weeks through Week 16. Analyses included CLASI‐20/50/70/90 responses (≥20%/50%/70%/90% decrease [improvement] from baseline in CLASI‐A score), 7‐point improvement from baseline in CLASI‐A score, subgroup analyses of percentage change in CLASI‐A scores by baseline characteristics and achievement of ‘clear’ (CLASI‐A scores of 0–1) or ‘almost clear’ (0–3) skin status. Shifts from baseline in skin condition were evaluated by the Physician's Global Assessment (PGA) of CLE and the Physician's Global Impression (PGI) of change in CLE.
Results
Greater proportions of litifilimab‐treated participants achieved CLASI‐20/50/70/90 responses (3.8%–72.1%) than placebo‐treated participants (0%–43.8%) at Week 16, with significant differences observed from Week 4 for CLASI‐20/50. From Weeks 4 to 16, more litifilimab‐treated participants had ≥7‐point CLASI‐A score decreases from baseline (13.8%–43.9%) compared with placebo (10.5%–21.1%). At Week 16, compared with placebo, more litifilimab‐treated participants achieved ‘clear’ or ‘almost clear’ skin status; CLASI‐A score improvements for subgroups were numerically higher with litifilimab, more litifilimab‐treated participants shifted from ‘severe’ or ‘moderate’ to ‘almost clear’ skin status based on PGA of CLE, and more litifilimab‐treated participants were ‘much improved’ based on PGI results.
Conclusions
These analyses provide additional evidence to support litifilimab efficacy in clearing skin disease activity, as demonstrated in the LILAC study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.
- Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA.
- Division of Rheumatology, Northwell Health, Great Neck, New York, USA.
- Division of Rheumatology, Autoimmunity and Inflammation, University of California, San Diego School of Medicine, La Jolla, California, USA.
- Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Förderung
- Biogen
Zitieren
APA
Werth, V. P., Merola, J. F., Furie, R., Kalunian, K., van Vollenhoven, R. F., Romero-Diaz, J., Li, Q., Yang, W., & Barbey, C. (2026). Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study. Journal of the European Academy of Dermatology and Venereology, 40(9), 1481-1489. https://doi.org/10.1111/jdv.70291
Vancouver
Werth VP, Merola JF, Furie R, Kalunian K, van Vollenhoven RF, Romero-Diaz J, et al. Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study. Journal of the European Academy of Dermatology and Venereology. 2026;40(9):1481-1489. doi:10.1111/jdv.70291
BibTeX
@article{Werth2026,
author = {Werth, Victoria P and Merola, Joseph F and Furie, Richard and Kalunian, Kenneth and van Vollenhoven, Ronald F and Romero-Diaz, Juanita and Li, Qianyun and Yang, Weihong and Barbey, Catherine},
title = {Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {9},
pages = {1481--1489},
doi = {10.1111/jdv.70291}
}
EUVIMED